PubMed 12 Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Kartha

PubMed 12. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994, 54:3929–3933.PubMed 13. Bringuier PP, Umbas R, Schaafsma

www.selleckchem.com/products/ganetespib-sta-9090.html HE, Karthaus HF, Debruyne FM, Schalken JA: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993, 53:3241–3245.PubMed 14. Dorudi S, Sheffield JP, Poulsom R, Northover JM, Hart IR: E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol 1993, 142:981–986.PubMed 15. Gervais ML, Henry PC, Saravanan A, Burry TN, Gallie BL, Jewett MA, Hill RP, Evans AJ, Ohh M: Nuclear

E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma. Lab Invest 2007, 87:1252–1264.PubMedCrossRef 16. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996, 382:638–642.PubMedCrossRef 17. Karim R, Tse G, Putti T, Scolyer R, Lee S: The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004, 36:120–128.PubMedCrossRef 18. Ronkainen H, Vaarala MH, Kauppila S, Soini Y, Paavonen TK, Rask J, Hirvikoski P: Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation Entinostat in renal cell carcinoma. Oncol Rep 2009, 21:1519–1523.PubMed 19. UICC: TNM Classification of Malignant Tumours. 6th edition. Wiley & Sons, New York; 2002. 20. IARC: Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon; 2004. 21. Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, Luo J: A novel role of myosin VI else in human prostate cancer.

Am J Pathol 2006, 169:1843–1854.PubMedCrossRef 22. Loikkanen I, Toljamo K, Hirvikoski P, Vaisanen T, Paavonen TK, Vaarala MH: Myosin VI is a modulator of androgen-dependent gene expression. Oncol Rep 2009, 22:991–995.PubMed 23. McGurk L, Tzolovsky G, Spears N, Bownes M: The temporal and spatial expression pattern of myosin Va, Vb and VI in the mouse ovary. Gene Expr Patterns 2006, 6:900–907.PubMedCrossRef 24. Yoshida H, Cheng W, Hung J, Montell D, Geisbrecht E, Rosen D, Liu J, Naora H: Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci USA 2004, 101:8144–8149.PubMedCrossRef 25. Guo L, Kuroda N, Miyazaki E, Hayashi Y, Toi M, Naruse K, Hiroi M, Ashida S, Shuin T, Enzan H: The complementary role of beta-catenin in diagnosing various subtypes of renal cell carcinomas and its up-regulation in conventional renal cell carcinomas with high nuclear grades. Oncol Rep 2001, 8:521–526.PubMed 26.

Comments are closed.